proteostasis therapeutics is discovering and developing novel small molecule therapeutics designed to control the body’s protein homeostasis, or proteostasis network. the proteostasis network maintains the body’s natural balance of proteins to protect us from numerous diseases. these novel therapies, or proteostasis regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the proteostasis network, such as alzheimer’s disease, emphysema, huntington’s disease, and type ii diabetes.
Company profile
Ticker
KA
Exchange
Website
CEO
Meenu Chhabra
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PROTEOSTASIS THERAPEUTICS INC, PROTEOSTASIS THERAPEUTICS, INC., YUMANITY THERAPEUTICS, INC.
SEC CIK
Corporate docs
Subsidiaries
Kineta Operating, LLC • Kineta Chronic Pain, LLC • Yumanity, Inc. ...
KA stock data
Latest filings (excl ownership)
8-K
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
8 Apr 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
21 Mar 24
8-K
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
12 Mar 24
8-K
Kineta Announces Restructuring and Exploration of Strategic Alternatives
29 Feb 24
8-K
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
17 Jan 24
8-K
Regulation FD Disclosure
5 Jan 24
8-K
Entry into a Material Definitive Agreement
15 Dec 23
EFFECT
Notice of effectiveness
15 Nov 23
424B3
Prospectus supplement
13 Nov 23
Latest ownership filings
4
Shawn Iadonato
16 Apr 24
4
CRAIG W. PHILIPS
16 Apr 24
4
Keith Baker
16 Apr 24
4
Thierry Guillaudeux
16 Apr 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13D/A
Iadonato Shawn
12 Feb 24
SC 13G/A
Magness Charles
12 Feb 24
4
Raymond J. Bartoszek
6 Dec 23
4
CRAIG W. PHILIPS
30 Nov 23
4
Shawn Iadonato
30 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.69 mm | 7.69 mm | 7.69 mm | 7.69 mm | 7.69 mm | 7.69 mm |
Cash burn (monthly) | 69.33 k | (no burn) | 1.33 mm | 3.21 mm | 76.33 k | 1.64 mm |
Cash used (since last report) | 459.12 k | n/a | 8.80 mm | 21.22 mm | 505.47 k | 10.83 mm |
Cash remaining | 7.23 mm | n/a | -1.11 mm | -13.54 mm | 7.18 mm | -3.14 mm |
Runway (months of cash) | 104.2 | n/a | -0.8 | -4.2 | 94.1 | -1.9 |
Institutional ownership, Q2 2023
25.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 17 |
Opened positions | 5 |
Closed positions | 3 |
Increased positions | 3 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 2.94 bn |
Total shares | 2.79 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Raymond J. Bartoszek | 878.88 k | $1.66 mm |
Armistice Capital | 876.00 k | $2.26 bn |
CBI USA | 721.11 k | $1.36 mm |
FMR | 123.72 k | $319.20 mm |
Vanguard | 61.56 k | $158.83 mm |
Artal | 31.06 k | $80.00 k |
Renaissance Technologies | 26.92 k | $69.00 k |
Financial Advocates Investment Management | 24.61 k | $63.49 mm |
BLK Blackrock | 20.74 k | $53.51 mm |
CIBC Asset Management | 13.52 k | $34.88 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Apr 24 | Keith Baker | Stock Option Common Stock | Grant | Acquire A | No | No | 0.36 | 225,000 | 81.00 k | 225,000 |
14 Apr 24 | Craig W. Philips | Stock Option Common Stock | Grant | Acquire A | No | No | 0.36 | 225,000 | 81.00 k | 225,000 |
14 Apr 24 | Shawn Iadonato | Stock Option Common Stock | Grant | Acquire A | No | No | 0.36 | 225,000 | 81.00 k | 225,000 |
14 Apr 24 | Thierry Guillaudeux | Stock Option Common Stock | Grant | Acquire A | No | No | 0.36 | 225,000 | 81.00 k | 225,000 |
6 Dec 23 | Raymond J. Bartoszek | Common Stock | Buy | Acquire P | No | No | 4.5 | 250 | 1.13 k | 17,206 |
5 Dec 23 | Raymond J. Bartoszek | Common Stock | Buy | Acquire P | No | No | 4.5 | 1,000 | 4.50 k | 16,956 |
4 Dec 23 | Raymond J. Bartoszek | Common Stock | Buy | Acquire P | No | No | 4.325 | 1,000 | 4.33 k | 15,956 |
News
Kineta Granted U.S. Patent Titled 'Proteasome activity enhancing compounds (including methods for treating cancer or tumors)'
16 Apr 24
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
15 Apr 24
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
10 Apr 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
10 Apr 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
10 Apr 24
Press releases
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
8 Apr 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
21 Mar 24
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium
22 Feb 24
Kineta to Present at Upcoming Investor Conferences
14 Feb 24
Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series
7 Feb 24